{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:55:36Z","timestamp":1762865736124},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.exphem.2010.09.005","type":"journal-article","created":{"date-parts":[[2010,9,24]],"date-time":"2010-09-24T10:26:17Z","timestamp":1285323977000},"page":"102-113.e1","source":"Crossref","is-referenced-by-count":11,"title":["Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy"],"prefix":"10.1016","volume":"39","author":[{"given":"Sari E.","family":"Jalkanen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Vakkila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kreutzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne K.","family":"Nieminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2010.09.005_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2010.09.005_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.005_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2010.09.005_bib4","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2010.09.005_bib5","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","article-title":"Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)","volume":"107","author":"Scherr","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib6","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1038\/sj.onc.1210758","article-title":"Aberrant cytokine signaling in leukemia","volume":"26","author":"Van Etten","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2010.09.005_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2010.09.005_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cyto.2009.01.010","article-title":"Peripheral tolerance in CD8+ T cells","volume":"46","author":"Srinivasan","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.exphem.2010.09.005_bib9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2010.09.005_bib10","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation","volume":"102","author":"Rezvani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","article-title":"Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells","volume":"111","author":"Molldrem","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2010.09.005_bib12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2141.2003.03979.x","article-title":"Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia","volume":"120","author":"Eisendle","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2010.09.005_bib14","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2003-09-3220","article-title":"Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia","volume":"103","author":"Mohty","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2010.09.005_bib16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2010.09.005_bib17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with\u00a0interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2010.09.005_bib18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.005_bib19","article-title":"Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"114","author":"Al-Ameri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.exphem.2010.09.005_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2010.09.005_bib22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.005_bib23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1365-2249.2001.01693.x","article-title":"Cytokine receptor signalling in neonatal macrophages: defective STAT-1 phosphorylation in response to stimulation with IFN-gamma","volume":"126","author":"Marodi","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2004.06.028","article-title":"Single cell profiling of potentiated phospho-protein networks in cancer cells","volume":"118","author":"Irish","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2010.09.005_bib25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jnci\/djh252","article-title":"Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy","volume":"96","author":"Lesinski","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2010.09.005_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jim.2006.03.014","article-title":"Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways CIPP] in human peripheral blood mononuclear cells","volume":"313","author":"Montag","year":"2006","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.exphem.2010.09.005_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2220\/biomedres.29.271","article-title":"Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines","volume":"29","author":"Tochizawa","year":"2008","journal-title":"Biomed Res"},{"key":"10.1016\/j.exphem.2010.09.005_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-3083.2007.02028.x","article-title":"A novel modification of a flow cytometric assay of phosphorylated STAT1 in whole blood monocytes for immunomonitoring of patients on IFN alpha regimen","volume":"67","author":"Vakkila","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.leukres.2009.11.008","article-title":"Molecular characterization and prognostic significance of FLT3 in CML progression","volume":"34","author":"Kim","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.09.005_bib30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrc1804","article-title":"Mapping normal and cancer cell signalling networks: towards single-cell proteomics","volume":"6","author":"Irish","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2010.09.005_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clim.2003.11.009","article-title":"Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications","volume":"110","author":"Krutzik","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nri1372","article-title":"Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses","volume":"4","author":"Seong","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.0902-4441.2003.00201.x","article-title":"Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients","volume":"72","author":"Gutierrez-Castellanos","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2010.09.005_bib36","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood.V77.6.1131.1131","article-title":"Molecular physiology of granulocyte-macrophage colony-stimulating factor","volume":"77","author":"Gasson","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1006\/cyto.2000.0666","article-title":"SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients","volume":"12","author":"Tao","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.exphem.2010.09.005_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.leu.2405104","article-title":"High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease","volume":"22","author":"Sergeeva","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.005_bib39","first-page":"331","article-title":"G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia","volume":"38","author":"Lee","year":"2008","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.exphem.2010.09.005_bib40","first-page":"7","article-title":"Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase","volume":"79","author":"Balleari","year":"1994","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2010.09.005_bib41","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/sj.onc.1205859","article-title":"Roles of activated Src and Stat3 signaling in melanoma tumor cell growth","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2010.09.005_bib42","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.159.10.4772","article-title":"Induction of tolerance by IL-10-treated dendritic cells","volume":"159","author":"Steinbrink","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4049\/jimmunol.172.1.567","article-title":"Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages","volume":"172","author":"Williams","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib44","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.190.7.995","article-title":"An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation","volume":"190","author":"Asseman","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2010.09.005_bib45","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2010.09.005_bib46","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1084\/jem.20052333","article-title":"Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1","volume":"203","author":"Kinjyo","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2010.09.005_bib47","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2010.09.005_bib48","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1038\/sj.onc.1208159","article-title":"Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis","volume":"23","author":"Silva","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2010.09.005_bib49","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.4049\/jimmunol.179.11.7593","article-title":"Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity","volume":"179","author":"Pallandre","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2010.09.005_bib50","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T- and NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.09.005_bib51","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","article-title":"Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro","volume":"18","author":"Cwynarski","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2010.09.005_bib52","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.09.005_bib53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","article-title":"The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro","volume":"127","author":"Blake","year":"2008","journal-title":"Clin Immunol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10004145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10004145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T18:55:50Z","timestamp":1711824950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X10004145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0301472X10004145"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2010.09.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}